114 results on '"Smit, V. T. H. B. M."'
Search Results
2. Tumoren van de vrouwelijke geslachtsorganen
3. Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy
4. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy
5. Prognostic value of tumor–stroma ratio combined with the immune status of tumors in invasive breast carcinoma
6. Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
7. Practical guidance for mismatch repair-deficiency testing in endometrial cancer
8. Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach
9. The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis
10. Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
11. The Diagnostic Value of One-Step Nucleic acid Amplification (OSNA) for Sentinel Lymph Nodes in Colon Cancer Patients
12. Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854)
13. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)
14. Quantitative assessment of lymph vascular space invasion (LVSI) provides important prognostic information in node-negative breast cancer
15. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy
16. Reliability of core needle biopsy for determining ER and HER2 status in breast cancer
17. The prognostic role of TGF-β signaling pathway in breast cancer patients
18. Expression of cell adhesion molecules and prognosis in breast cancer
19. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial
20. Lymphogranuloma venereum proctocolitis: mucosal T cell immunity of the rectum associated with chlamydial clearance and clinical recovery
21. Erratum to: Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach
22. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
23. Prognostic value of tumor–stroma ratio combined with the immune status of tumors in invasive breast carcinoma
24. Tumor-infiltrating lymphocytes, tumor-associated macrophages and HLA class 1 expression in breast cancer patients treated with neoadjuvant chemotherapy with or without zoledronic acid: A sub study of the NEOZOTAC trial
25. LBA63 - Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy
26. Comment on: The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer
27. Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma
28. Expression of cell adhesion molecules and prognosis in breast cancer
29. Validation study of the prognostic value of cyclin-dependent kinase (CDK)-based risk in Caucasian breast cancer patients
30. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
31. Improved interpretation of complex chromosomal rearrangements by combined GTG banding and in situ suppression hybridization using chromosome-specific libraries and cosmid probes
32. Flow cytometric DNA-ploidy analysis of synchronously occurring multiple malignant tumors of the female genital tract
33. Multifocal adrenal nerve tissue?
34. Patterns of recurrence in the randomised PORTEC-3 trial of chemoradiotherapy for endometrial cancer
35. Cyclin-dependent kinase 1 and 2 activity as prognostic markers in early breast cancer
36. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas
37. Comment on: The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer.
38. Accuracy in Diagnosis of Celiac Disease Without Biopsies in Clinical Practice
39. NEO-ZOTAC: Toxicity data of a phase III randomized trial with NEOadjuvant chemotherapy (TAC) with or without ZOledronic acid (ZA) for patients with HER2-negative large resectable or locally advanced breast cancer (BC).
40. Microcystic elongated and fragmented (MELF) pattern of invasion: Molecular features and prognostic significance in the PORTEC-1 and -2 trials.
41. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial.
42. Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe.
43. Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report.
44. Tumour-free margins in vulvar squamous cell carcinoma: Does distance really matter?
45. Vitamin D (25-0H D3) status and pathological response to neoadjuvant chemotherapy in stage II/III breast cancer: Data from the NEOZOTAC trial (BOOG 10-01).
46. Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial.
47. Pediatric germ cell tumors presenting beyond childhood?
48. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.
49. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
50. Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.